Mohammad Hirmand, M.D., serves as executive vice president and chief medical officer (CMO) of Turning Point Therapeutics, responsible for clinical development, clinical operations and regulatory affairs. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, most recently as CMO of Peloton Therapeutics, which was acquired by Merck in July 2019.
Prior to joining Peloton in 2017, Dr. Hirmand served as CMO of Medivation through its acquisition by Pfizer. He played a vital role in advancing XTANDI® (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase (PARP) inhibitor, talazoparib. Before his 10-year tenure at Medivation, he held clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. (now part of Amgen), and Theravance Biopharma, Inc.
Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.
What is Mohammad Hirmand's net worth?
The estimated net worth of Mohammad Hirmand is at least $2.99 million as of March 4th, 2016. Dr. Hirmand owns 39,342 shares of Turning Point Therapeutics stock worth more than $2,990,385 as of November 25th. This net worth estimate does not reflect any other investments that Dr. Hirmand may own. Additionally, Dr. Hirmand receives a salary of $783,770.00 as EVP at Turning Point Therapeutics. Learn More about Mohammad Hirmand's net worth.
How old is Mohammad Hirmand?
Dr. Hirmand is currently 52 years old. There are 4 older executives and no younger executives at Turning Point Therapeutics. The oldest executive at Turning Point Therapeutics is Mr. Paolo Tombesi, Exec. VP & CFO, who is 58 years old. Learn More on Mohammad Hirmand's age.
What is Mohammad Hirmand's salary?
As the EVP of Turning Point Therapeutics, Inc., Dr. Hirmand earns $783,770.00 per year. The highest earning executive at Turning Point Therapeutics is Dr. Athena Maria Countouriotis M.D., Pres, CEO & Director, who commands a salary of $1,190,000.00 per year. Learn More on Mohammad Hirmand's salary.
How do I contact Mohammad Hirmand?
Has Mohammad Hirmand been buying or selling shares of Turning Point Therapeutics?
Mohammad Hirmand has not been actively trading shares of Turning Point Therapeutics in the last ninety days. Most recently, Mohammad Hirmand sold 1,253 shares of the business's stock in a transaction on Tuesday, January 5th. The shares were sold at an average price of $120.00, for a transaction totalling $150,360.00. Learn More on Mohammad Hirmand's trading history.
Who are Turning Point Therapeutics' active insiders?
